Pfizer Limited has announced significant changes in its senior management team, informing stock exchanges of two key departures scheduled for 2026. The pharmaceutical company submitted the mandatory disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on March 31, 2026.

Senior Management Departures

The company has reported two distinct changes affecting its senior leadership structure:

Regulatory Compliance

Pfizer Limited has fulfilled its regulatory obligations by submitting the required documentation to both BSE Limited and the National Stock Exchange of India. The company provided Mr. Deepak Rakheja's resignation letter as Annexure A, complying with SEBI Listing Regulations 2015 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

In his resignation letter dated March 31, 2026, Mr. Rakheja expressed gratitude to the management and colleagues for their support during his tenure with the company. He confirmed his departure effective close of business hours on July 8, 2026, to pursue opportunities outside Pfizer.

Corporate Communication

The disclosure was signed by Prajeet Nair, Director – Corporate Services & Company Secretary, and submitted digitally on March 31, 2026. The company requested stock exchanges to take the information on record, ensuring transparency in corporate governance and compliance with listing requirements.

These management changes represent routine corporate transitions within the pharmaceutical company's organizational structure, with both departures following proper regulatory disclosure procedures.

Pfizer Limited has announced strategic changes to its senior management team, effective February 1, 2026, as part of an organizational restructuring across key business divisions. The pharmaceutical company informed stock exchanges about these appointments and transitions on January 20, 2026, in compliance with SEBI listing regulations.

Key Management Appointments and Changes

The company has made three significant changes to its senior management structure:

New Vaccine Division Leadership

Mr. Nilesh Pendse brings extensive pharmaceutical industry experience to his new role as Category Lead – Vaccines. He joined Pfizer Products India Private Limited in 2024, where he led the Oncology Business, focusing on strategic growth, market access, and stakeholder engagement to advance cancer care.

Prior to joining Pfizer, Mr. Pendse held leadership positions at prominent pharmaceutical companies including Boehringer Ingelheim and Novartis, where he managed diabetes and neurosciences divisions with focus on sales, marketing, and franchise operations. His background also includes consulting experience with Boston Consulting Group, Ernst & Young, and Accenture, leading projects in strategy, revenue acceleration, and business transformation.

Educational Background and Qualifications

Mr. Pendse holds strong academic credentials for his leadership role:

• MBA in Marketing from Jamnalal Bajaj Institute of Management Studies
• Bachelor's degree in Electronics Engineering from the University of Mumbai

Organizational Restructuring Details

Mr. Manikantan Seshadrinathan, who currently serves as Category Lead for Hospitals & Rare Disease, will transition to another role within the broader Pfizer Group Companies. His departure from the Indian operations creates an opportunity for organizational realignment.

Mr. Prashant Mahalingam will expand his current responsibilities by taking on additional oversight of the Hospitals Business. His redesignation to Category Lead – Internal Medicine & Hospitals reflects the company's strategy to consolidate related business areas under experienced leadership. Pfizer had previously informed stock exchanges about Mr. Mahalingam's profile and details when he was appointed as Category Lead – Internal Medicine on November 5, 2024.

Compliance and Governance

The company has fulfilled all regulatory disclosure requirements under SEBI Listing Regulations 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. Mr. Pendse holds no shares in the company and has no relationships with existing directors, key managerial personnel, or senior management personnel, ensuring independence in his new role.